ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2816

Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature

Takahiro Sato, Matteo Cesaroni, Jessica Schreiter, Jarrat Jordan, Marc Chevrier and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus and autoantibodies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide range of clinical manifestations. Production of autoantibodies is a hallmark of SLE and has been shown to contribute to disease pathogenesis as well as specific clinical manifestations such as nephritis. Despite the importance of autoantibodies in SLE, only a limited number of autoantibodies have been characterized and are utilized as lupus biomarkers, and many of these are not specific for lupus. We sought to address the question of whether broad autoantibody specificity profiling could identify novel and more specific autoantibodies to identify SLE patients, and if certain autoantibody specificities were enriched in patients exhibiting an interferon-I (IFN-I) signature.

Methods: To address this question, we carried out an unbiased analysis using the ProtoArray® platform (detection of >9400 autoantibodies), comparing five racially and ethnically diverse cohorts containing patients of African American, European, and Chinese descent (total of 131 healthy and 193 SLE patients).

Results: Each cohort had a group of SLE patients exhibiting very high autoantibody signals, a group that had moderate signal, and a group that had low signal against most of the 9400 autoantigens. The majority of healthy patients had very low autoantibody signals. Furthermore, we identified a core set of 17 autoantibodies that were significantly upregulated (FC>2, FDR<0.01) in SLE patients compared to healthy patients across all five cohorts. The levels of these core autoantibodies remained longitudinally stable over a 12-week period. We also demonstrated that the expression of these 17 autoantibodies correlated with levels of an interferon (IFN) signature present in whole blood from these patients.

Conclusion: Despite the diverse set of patients in our study, we were able to identify a small set of core autoantibodies that were commonly upregulated in SLE patients in all five cohorts. Importantly, we demonstrate that autoantibodies could be vital in patient stratification or as a biomarker of SLE, as our study reveals that levels of autoantibodies are potentially linked with IFN-I gene signatures.


Disclosure: T. Sato, Janssen Research and Development, LLC, 3; M. Cesaroni, Janssen Research and Development, LLC, 3; J. Schreiter, Janssen Research and Development, LLC., 3,Janssen Research and Development, LLC., 1; J. Jordan, Janssen Research and Development, LLC., 3; M. Chevrier, Janssen Research and Development, LLC., 1,Janssen Research and Development, LLC., 3; J. Benson, Janssen Research and Development, LLC., 3,Janssen Research and Development, LLC., 1.

To cite this abstract in AMA style:

Sato T, Cesaroni M, Schreiter J, Jordan J, Chevrier M, Benson J. Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/broad-autoantibody-profiling-in-ethnically-diverse-sle-cohorts-reveals-a-set-of-conserved-autoantibodies-that-are-correlated-to-a-type-i-interferon-signature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/broad-autoantibody-profiling-in-ethnically-diverse-sle-cohorts-reveals-a-set-of-conserved-autoantibodies-that-are-correlated-to-a-type-i-interferon-signature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology